Huadong Medicine Co., Ltd.
The First Quarterly Report 2021
April 2021
Section I Important Declaration
The Board of Directors, Board of Supervisors, directors, supervisors and senior
management of Huadong Medicine Co., Ltd. (hereinafter referred to as the
“Company”) hereby guarantee that the information presented in this report is
authentic, accurate and complete and free of any false records, misleading
statements or material omissions, and shall undertake individual and joint legal
liabilities.
All directors have attended the board of directors meeting to review this
quarterly report.
Lv Liang, the Company’s legal representative and the officer in charge of
accounting, and Qiu Renbo, head of accounting department (accounting
supervisor) hereby declare and guarantee that the financial statements in this
quarterly report are authentic, accurate and complete.
According to “Stock Listing Rules of the Shenzhen Stock Exchange”, if listed
companies have both Chinese or other language version of public notice, they
should ensure the content of both versions are the same. In the case of
discrepancy, the originalversion in Chinese shallprevail.
Section II Company Profile
I. Key Accounting Data and Financial Indicators
Whether the Company needs to perform retroactive adjustment or restatement of previous accounting data
□Yes √ No
Change of the current
The current reporting period Same period last year reporting period over the
same period last year
Operating revenue (yuan) 8,896,632,277.36 8,598,069,911.29 3.47%
Net profit attributable to shareholders of
758,380,756.56 1,147,278,457.64 -33.90%
listed companies (yuan)
Net profit attributable to shareholders of
listed companies after deducting 695,792,411.78 856,930,262.10 -18.80%
non-recurring gains/losses (yuan)
Net cash flow from operating activities
(yuan) 302,314,164.48 218,779,623.89 38.18%
Basic earnings per share (yuan/s hare) 0.4334 0.6557 -33.90%
Diluted earnings per share (yuan/share) 0.4334 0.6557 -33.90%
Weighted average return on equity (ROE) 5.04% 8.89% -3.85%
Change of the end of the
End of the current reporting current reporting period
End of last year
period
over the end of last year
Totalassets (yuan) 26,096,806,585.74 24,201,348,154.75 7.83%
Net assets attributable to shareholders of
15,266,793,123.79 14,619,821,308.60 4.43%
listed companies (yuan)
Items and amounts of non-recurring gains/losses
√Applicable □ N/A
Unit: RMB yuan
Amount (from the beginning
Item of the year to the end of the Note
reporting period)
Gains/losses on disposa lof non-current assets (including the
written-off part of the accrued assets impairment reserve) 15,675.63
Government grants included in current gains/losses (excluding
those closely related to operating activities, or regular government 76,459,624.41
grants)
Other non-operating income or expenditure -2,351,230.65
Less:Amount affected by income tax 11,433,797.38
Amount affected by minority interest (after tax) 101,927.23
Total 62,588,344.78 --
If the Company recognizes an ite m as a non-recurring gain/loss based on the “Interpretation Announcement on Information
Disclosure Criteria for Public Companies No. 1 – Non-Recurring Profit/Loss” or recognizes an item satisfying the definition of
non-recurring profit/loss in the announcement as a recurring profit/loss, reasons should be specified.
□Applicable √ N/A
No such case during the reporti
查看PDF原文
